Article
Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.
Breast cancer research : BCR - 11 Aug 2020
Kurozumi Sasagu, Alsaleem Mansour, Monteiro Cíntia J, Bhardwaj Kartikeya, Joosten Stacey E P, Fujii Takaaki, Shirabe Ken, Green Andrew R, Ellis Ian O, Rakha Emad A, Mongan Nigel P, Heery David M, Zwart Wilbert, Oesterreich Steffi, Johnston Simon J
Abstract excerpt
BACKGROUND: Invasive lobular carcinoma (ILC) accounts for 10-15% of primary breast cancers and is typically estrogen receptor alpha positive (ER+) and ERBB2 non-amplified. Somatic mutations in ERBB2/3 are emerging as a tractable mechanism underlying enhanced human epidermal growth factor 2 (HER2) activity. We tested the hypothesis that therapeutically targetable ERBB2/3 mutations in primary ILC of the breast...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.